- Evofem Biosciences Announces Financial Results for the First Quarter of 2024
- Evofem Strengthens Phexxi Intellectual Property with New Composition of Matter Patent From USPTO
- Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023
- Evofem Negotiates Improved Rebate for Hormone-Free "In the Moment" Contraceptive PHEXXI with Medi-Cal
- For Women Using GLP-1 Receptor Agonists who take Oral Birth Control Pills, Hormone-Free Phexxi Contraceptive Gel is a Logical Solution to Help Prevent Unintended Pregnancy
More ▼
Key statistics
As of last trade, Evofem Biosciences Inc (EVFM:QBB) traded at 0.014, 40.00% above the 52 week low of 0.01 set on May 06, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.0154 |
---|---|
High | 0.0154 |
Low | 0.0122 |
Bid | -- |
Offer | -- |
Previous close | 0.0129 |
Average volume | 2.04m |
---|---|
Shares outstanding | 62.06m |
Free float | 62.06m |
P/E (TTM) | 0.0014 |
Market cap | 799.34k USD |
EPS (TTM) | -5.92 USD |
Data delayed at least 15 minutes, as of May 23 2024 18:41 BST.
More ▼